<!DOCTYPE html>
<html><head><style>table, th, td {border: 1px solid black;border-collapse: collapse;}</style></head>
<table colsep="0" frame="topbot" id="tbl0001" trsep="0" xmlns="http://www.elsevier.com/xml/common/cals/dtd">
<label>
        Table 1
       </label>
<caption id="cap0004">
<simple-para id="spara004" view="all">
         Scenarios characterising disruption to HIV services due to the COVID-19 epidemic.
        </simple-para>
</caption>

<tgroup cols="2">
<colspec align="left" colname="col1" colnum="1"/>
<colspec align="left" colname="col2" colnum="2"/>
<thead>
<tr trsep="1">
<td colname="col1" id="en0001" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           Scenario
          </td>
<td colname="col2" id="en0002" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           Assumed Impact on HIV Programs
          </td>
</tr>
</thead>
<tbody>
<tr>
<td colname="col1" id="en0003" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           1. Managed pause (least severe)
          </td>
<td colname="col2" id="en0004" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           -No new ART enrolments
           <br/>
           -No new VMMCs
           <br/>
           -(No new PrEP enrolments
           
           )
           <br/>
           -Sexual contacts decrease by 10%
          </td>
</tr>
<tr>
<td colname="col1" id="en0005" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           2. Managed disruption
          </td>
<td colname="col2" id="en0006" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           -No new ART enrolments
           <br/>
           -No new VMMCs
           <br/>
           -(No PrEP enrolment or prescription refills
           
           )
           <br/>
           -Viral suppression decreases by 10% across individuals on ART
           <br/>
           -Condom use decreases by 50%
           <br/>
           -Sexual contacts decrease by 10%
          </td>
</tr>
<tr>
<td colname="col1" id="en0007" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           3. Interruption of supply (most severe)
          </td>
<td colname="col2" id="en0008" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           -No new ART enrolments
           <br/>
           -No new VMMCs
           <br/>
           -(No PrEP enrolment or prescription refills
           
           )
           <br/>
           -Viral suppression decreases by 10% across individuals on ART
           <br/>
           -40% of individuals on ART go off ART for duration of disruption, assuming a mean monthly mortality risk of 0.24% during the disruption
           
<br/>
           -Condom use decreases by 50%
           <br/>
           -Sexual contacts decrease by 10%
          </td>
</tr>
</tbody>
</tgroup>
<table-footnote id="tb1fn1">

<note-para id="notep0001" view="all">
         PrEP coverage is assumed to be very low and does not affect directly results presented here.
        </note-para>
</table-footnote>
<table-footnote id="tb1fn2">

<note-para id="notep0002" view="all">
         We optimistically assume that if individuals have stopped ART due to the COVID-19 disruption, they immediately return to ART once supply resumes and their long-term prognosis on ART is not affected by the interruption in ART usage.
        </note-para>
</table-footnote>
</table>
</html>
<!DOCTYPE html>
<html><head><style>table, th, td {border: 1px solid black;border-collapse: collapse;}</style></head>
<table colsep="0" frame="topbot" id="tbl0003" trsep="0" xmlns="http://www.elsevier.com/xml/common/cals/dtd">
<label>
        Table 3
       </label>
<caption id="cap0006">
<simple-para id="spara006" view="all">
         Alternative assumptions used for the risk of death experienced by those PLHIV whose ART supply is interrupted.
        </simple-para>
</caption>

<tgroup cols="4">
<colspec align="left" colname="col1" colnum="1"/>
<colspec align="left" colname="col2" colnum="2"/>
<colspec align="left" colname="col3" colnum="3"/>
<colspec align="left" colname="col4" colnum="4"/>
<thead>
<tr trsep="1">
<td colname="col1" id="en0025" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd"/>
<td colname="col2" id="en0026" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Average monthly mortality risk
           </italic>
</td>
<td colname="col3" id="en0027" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Proportion that would die after one year
           </italic>
</td>
<td colname="col4" id="en0028" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Justification
           </italic>
</td>
</tr>
</thead>
<tbody>
<tr>
<td colname="col1" id="en0029" role="trhead" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Lower bound
           </italic>
</td>
<td colname="col2" id="en0030" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.10%
          </td>
<td colname="col3" id="en0031" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           1.24%
          </td>
<td colname="col4" id="en0032" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           This is a hypothetical best-case scenario in which the vast majority of individuals do not deteriorate rapidly.
          </td>
</tr>
<tr>
<td colname="col1" id="en0033" role="trhead" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Medium
           </italic>
</td>
<td colname="col2" id="en0034" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.24%
          </td>
<td colname="col3" id="en0035" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           2.91%
          </td>
<td colname="col4" id="en0036" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           The SMART trial found a 3% risk at 12 months of either death of an opportunistic infection for those with interrupted ART
           
           . This also implies a mean survival time approximately equivalent to that for HIV-positive persons who have never been on ART
           
           .
          </td>
</tr>
<tr>
<td colname="col1" id="en0037" role="trhead" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
<italic>
            Upper bound
           </italic>
</td>
<td colname="col2" id="en0038" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           0.44%
          </td>
<td colname="col3" id="en0039" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           5.28%
          </td>
<td colname="col4" id="en0040" valign="top" xmlns="http://www.elsevier.com/xml/common/dtd">
           This is the hypothetical worst-case scenario in which many persons deteriorate more rapidly.
          </td>
</tr>
</tbody>
</tgroup>
</table>
</html>
